Biotech company NsGene raises extra cash for clinical studies  

2005.05.05
Danish Biotech company NsGene has gained a DKK 30 mn (USD 5.1 mn) investment, which will enable the firm to move its R&D programmes into clinical studies and achieve significant milestones over the next 18 months

Danish Biotech company NsGene has gained a DKK 30 mn (USD 5.1 mn) investment which will enable the firm to move its R&D programmes into clinical studies and achieve significant milestones over the next 18 months. The financing was raised from existing investors including NeuroSearch, Dansk Kapitalanlæg and Karolinska Investment Fund, as well as from a new investor, the Danish Fund for Industrial Growth.

NsGene has three programmes in pre-clinical development. Two of these are biodelivery programmes for the treatment of Alzheimer's and Parkinson's disease respectively, and one programme is in collaboration with Biogen Idec regarding Neublastin for the treatment of naturopathic pain. The news is reported by financial daily newspaper Børsen.

NsGene was founded in December 1999 as a spin-off from the Danish biopharmaceutical company, NeuroSearch. NsGene develops novel cell and gene based products for the treatment of neurological diseases. One of the company's corner stones has been the discovery and patenting of the protein Neublastin, a GDNF (Glial cell derived neurotrophic factor) with potent neuroprotective effects. NsGene is based in Ballerup close to Copenhagen.

Link > NsGene 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×